All In MedTech

Device Trial Radar · NCT06611098

New Treatment of Knee Osteoarthritis

A Randomized, Controlled, Prospective and Multicenter Clinical Investigation Evaluating the Safety and Performance of ABIO3419 in Treating Knee Osteoarthritis.

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Feb 21, 2025

Primary completion

Nov 1, 2025

Study completion Feb 13, 2026

Sponsor

Lead sponsor
SymateseNot on our public-company list
Sponsor type
Industry
First posted
Sep 24, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 35 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Osteoarthritis (OA) is a chronic degenerative joint disease characterized macroscopically by progressive damage of articular cartilage, joint space narrowing, subchondral bone remodelling, joint marginal osteophyte formation and synovitis. It is also characterized by a decrease of the concentration and molecular weight of the hyaluronic acid in the synovial fluid which ultimately leads to poor viscoelastic properties of synovial fluid and induction of proinflammatory pathways. The intra-articular injection of viscosupplementation gel (mainly exogenous hyaluronic acid) represents one of the most used therapeutic strategies to treat osteoarthritis symptoms. Several studies on knee Osteoarthritis, have shown that one or more weekly injection of viscosupplementation gel significantly relieves articular pain and ameliorates mobility and joint function for at least 6 months and more. Repeated courses of intra-articular injections are an effective and safe treatment for knee osteoarthritis symptoms. Based on studies conducted on intra-articular viscosupplementation gels, the most common side effects expected are local transient and short-lived adverse events such as pain, swelling and arthralgia in the site of administration, which are fully reversible in the days following the injection. Furthermore, such local effects may occur in a minority of cases and are usually treated conservatively with ice, non-steroidal anti-inflammatory drugs, and relative rest.

Conditions

  • Knee Osteoarthristis

Interventions

  • ViscosupplementsDevice

    intra-articular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the performance of ABIO3419 treatment versus the comparator in subjects at 3 months (V7) by assessing knee pain while walking on flat ground.Time frame: Month 3 after the last injection

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • IRIS CRO

    Mtskheta, Georgia

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.